$1.08
4.42% day before yesterday
NYSE, Dec 24, 10:43 pm CET
ISIN
US44486Q1031
Symbol
HUMA

Humacyte Stock price

$1.08
-0.20 15.63% 1M
-1.15 51.57% 6M
-3.97 78.61% YTD
-3.43 76.05% 1Y
-1.22 53.04% 3Y
-8.91 89.19% 5Y
-8.59 88.83% 10Y
-8.59 88.83% 20Y
NYSE, Closing price Wed, Dec 24 2025
-0.05 4.42%
ISIN
US44486Q1031
Symbol
HUMA
Industry

Key metrics

Basic
Market capitalization
$208.4m
Enterprise Value
$221.9m
Net debt
$13.4m
Cash
$19.5m
Shares outstanding
158.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
132.8 | 69.0
EV/Sales
141.3 | 73.5
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-38.2%
Return on Equity
282.9%
ROCE
-159.7%
ROIC
-168.6%
Debt/Equity
-6.9
Financials (TTM | estimate)
Revenue
$1.6m | $3.0m
EBITDA
$-97.9m | $-60.5m
EBIT
$-105.3m | $-102.2m
Net Income
$-37.0m | $-39.2m
Free Cash Flow
$-106.0m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
6.9% | 43.4%
EBIT
6.3% | 10.4%
Net Income
75.8% | 73.7%
Free Cash Flow
-14.3%
Margin (TTM | estimate)
Gross
60.5%
EBITDA
-6,233.9% | -2,003.5%
EBIT
-6,702.8%
Net
-2,357.0% | -1,298.7%
Free Cash Flow
-6,743.9%
More
EPS
$-0.2
FCF per Share
$-0.7
Short interest
20.8%
Employees
219
Rev per Employee
$0.0
Show more

Is Humacyte a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Humacyte Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Humacyte forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Humacyte forecast:

Buy
85%
Hold
15%

Financial data from Humacyte

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
1.57 1.57
-
100%
- Direct Costs 0.62 0.62
-
39%
0.95 0.95
-
61%
- Selling and Administrative Expenses 31 31
27% 27%
1,974%
- Research and Development Expense 55 55
38% 38%
3,484%
-98 -98
7% 7%
-6,238%
- Depreciation and Amortization 7.37 7.37
2% 2%
469%
EBIT (Operating Income) EBIT -105 -105
6% 6%
-6,707%
Net Profit -37 -37
76% 76%
-2,359%

In millions USD.

Don't miss a Thing! We will send you all news about Humacyte directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Humacyte Stock News

Neutral
GlobeNewsWire
4 days ago
- Results published in Journal of Vascular Surgery Cases, Innovations and Techniques (JVS-CIT) -  - After up to 36 months of follow-up, patients demonstrated high limb salvage, low rates of infection, no unprovoked structural failures - - Results represent first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit - DURHAM, N.C., Dec. 22, 2025 (GLOBE N...
Neutral
GlobeNewsWire
10 days ago
DURHAM, N.C., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that it has entered into a credit facility with Avenue Venture Opportunities Fund II, L.P.
Neutral
GlobeNewsWire
about one month ago
– Post-implantation analysis of ATEVs demonstrates progressive recellularization with host cells, transforming the ATEV into a multi-layered living tissue similar to that of native blood vessels –    – Positive outcomes for dialysis patients suffering from Steal syndrome who were treated with the ATEV – – Additional presentations report durable two-year outcomes for patients treated in Ukraine ...
More Humacyte News

Company Profile

Humacyte, Inc. engages in the business of developing and manufacturing off-the-shelf, universally implantable, bioengineered human tissues, advanced tissue constructs, and organ systems with the goal of improving the lives of patients and transforming the practice of medicine. The company was founded by Laura E. Niklason, Shannon Dahl, and Juliana L. Blum on October 13, 2004 and is headquartered in Durham, NC.

Head office United States
CEO Laura Niklason
Employees 219
Founded 2004
Website humacyte.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today